Transition Therapeutics is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The Company’s lead CNS drug candidate is ELND005 for the treatment of agitation/aggression associated with Alzheimer’s disease, bipolar disorder and Down syndrome. Transition’s lead metabolic drug candidate is TT401 for the treatment of type 2 diabetes and accompanying obesity.

www.transitiontherapeutics.com